Skindex-Mini Among Patients With Melanoma Who Have Cutaneous Immunotherapy-Related Adverse Effects

Abstract

Keywords

melanoma immunotherapy itch Skindex-mini quality of life

Get full access to this article

View all access options for this article.

References

Plachouri

K-M.

Vryzaki

Georgiou

. Cutaneous adverse events of immune checkpoint inhibitors: a summarized overview. Curr Drug Saf. 2019;14(1):14-20.doi:10.2174/1574886313666180730114309

30058498

Chren

MM.

Lasek

RJ.

Sahay

AP.

Sands

. Measurement properties of Skindex-16: a brief quality-of-life measure for patients with skin diseases. J Cutan Med Surg. 2001;5(2):105-110.doi:10.1177/120347540100500202

11443481

Swerlick

RA.

Zhang

Patel

Chren

MM.

Chen

. The Skindex-mini: a streamlined quality of life measurement tool suitable for routine use in clinic. J Am Acad Dermatol. 2021;85(2):510-512.doi:10.1016/j.jaad.2018.12.035

30590072

Landis

JR.

Koch

. The measurement of observer agreement for categorical data. Biometrics. 1977;33(1):159-174.doi:10.2307/2529310

843571

Sznol

Ferrucci

PF.

Hogg

et al. Pooled analysis safety profile of nivolumab and ipilimumab combination therapy in patients with advanced melanoma. J Clin Oncol. 2017;35(34):3815-3822.doi:10.1200/JCO.2016.72.1167

28915085